The Birch Pollen Allergy drugs in development market research report provides comprehensive information on the therapeutics under development for Birch Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Birch Pollen Allergy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued products.
GlobalData tracks six drugs in development for Birch Pollen Allergy by six companies/universities/institutes. The top development phase for Birch Pollen Allergy is phase iii with three drugs in that stage. The Birch Pollen Allergy pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Birch Pollen Allergy pipeline products market are: Allergy Therapeutics, Roxall Medizin and Regeneron Pharmaceuticals.
The key targets in the Birch Pollen Allergy pipeline products market include Pollen Allergen Bet v 1.
The key mechanisms of action in the Birch Pollen Allergy pipeline product include Pollen Allergen Bet v 1 Inhibitor with one drug in Phase III. The Birch Pollen Allergy pipeline products include two routes of administration with the top ROA being Subcutaneous and three key molecule types in the Birch Pollen Allergy pipeline products market including Allergenics (Allergen), and Monoclonal Antibody.
Birch Pollen Allergy overview
Birch pollen allergy is a reaction which occurs soon after exposure to the pollen of birch trees. Signs and symptoms include skin reactions, such as hives, redness, or swelling; itching or tingling in or around the mouth and throat; digestive problems such as diarrhea, stomach cramps, nausea, or vomiting; tightening of the throat; shortness of breath or wheezing; and runny nose. Predisposing factors include age, family history, and other allergies. Treatment includes antihistamine drugs.
For a complete picture of Birch Pollen Allergy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
